Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron in Obesity or Overweight With and Without Type 2 Diabetes
jRCT2051250040Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of orforglipron in obesity, Overweight and type 2 diabetes mellitus (T2DM) (10 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants Allocated to Each Study. Started Jun 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2051250040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250040.